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Abstract
Background
A major cause of disability in secondary progressive multiple sclerosis (SPMS)
is progressive brain atrophy, whose pathogenesis is not fully understood. The
objective of this study was to identify protein biomarkers of brain atrophy in
SPMS.
 
Methods
We used surface-enhanced laser desorption-ionization time-of-flight mass
spectrometry to carry out an unbiased search for serum proteins whose
concentration correlated with the rate of brain atrophy, measured by serial MRI
scans over a 2-year period in a well-characterized cohort of 140 patients with
SPMS.  Protein species were identified by liquid chromatography-electrospray
ionization tandem mass spectrometry.
 
Results
There was a significant (p<0.004) correlation between the rate of brain atrophy
and a rise in the concentration of proteins at 15.1 kDa and 15.9 kDa in the
serum.  Tandem mass spectrometry identified these proteins as
alpha-haemoglobin and beta-haemoglobin, respectively.  The abnormal
concentration of free serum haemoglobin was confirmed by ELISA (p<0.001). 
The serum lactate dehydrogenase activity was also highly significantly raised
(p<10 ) in patients with secondary progressive multiple sclerosis. 
 
Conclusions
An underlying low-grade chronic intravascular haemolysis is a potential source
of the iron whose deposition along blood vessels in multiple sclerosis plaques
contributes to the neurodegeneration and consequent brain atrophy seen in
progressive disease. Chelators of free serum iron will be ineffective in
preventing this neurodegeneration, because the iron (Fe ) is chelated by
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preventing this neurodegeneration, because the iron (Fe ) is chelated by
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Introduction
In multiple sclerosis (MS), progressive disease develops in over half 
of those who present with an initial relapsing phase – secondary 
progressive MS (SPMS) – but can also present as primary pro-
gressive MS (PPMS). Progressive MS, for which there is no clear 
disease-modifying treatment1–3, accounts for much of the disability 
and the cost of MS to both the person and the community4.
Unlike relapsing-remitting MS (RRMS), where an inflammatory 
response involving the adaptive immune system leads to episodic 
neurological deficits, in progressive MS neuroaxonal loss leads to 
an increasing neurological deficit and brain atrophy5,6. However, in 
all forms of the disease, both the initiating events and the mecha-
nisms of pathogenesis remain uncertain5. Pseudoatrophy may 
account for some loss of brain volume7, but brain atrophy has also 
been associated with changes in neurofilament levels8 and sodium 
metabolism9.
The objective of the present study was to use an unbiased, 
high-throughput technique to identify protein biomarkers of 
brain atrophy in a longitudinal cohort of patients with SPMS. We 
used surface-enhanced laser desorption-ionization time-of-flight 
(SELDI-TOF) mass spectrometry to analyse serial serum samples 
from the population that participated in the MS-STAT study 
(described below)1, to identify proteins whose abundance was 
associated with MRI-measured brain atrophy rate. Serum 
proteomics in MS has previously been investigated in small 
cross-sectional studies to compare relapsing MS and progres-
sive disease10–12. However, these previous studies were neither 
designed nor powered to identify correlates of neurodegeneration in 
SPMS.
We found that the rate of brain atrophy in this cohort was associ-
ated with an increase in the concentration of free haemoglobin in 
the serum. This association was independent of the beneficial effect 
of simvastatin treatment, which remained significant in the present 
analysis. An ELISA assay confirmed the presence of abnormal 
concentrations of free haemoglobin in the serum of patients with 
SPMS. In addition, the serum lactate dehydrogenase (LDH) activity 
was significantly greater in patients with SPMS than in three differ-
ent groups of control subjects. These results suggest that chronic 
intravascular haemolysis releases haemoglobin into the serum in 
SPMS; we postulate that this haemoglobin is a source of the abnor-
mal iron deposition along blood vessels in the central nervous sys-
tem that is associated with neurodegeneration in progressive MS.
Methods
Ethical approval
The study was done in accordance with Good Clinical Practice 
and the Declaration of Helsinki. The protocol was approved by the 
UK National Research Ethics Service (Berkshire Research Ethics 
Committee; reference 07/Q1602/73), and every patient gave written 
informed consent before entering the study.
Subjects
The MS-STAT clinical trial was registered with ClinicalTrials.gov 
(NCT00647348) and has been described in detail elsewhere1. In 
this phase 2 placebo-controlled double-blind trial, 140 patients with 
SPMS were randomized 1:1 to simvastatin 80 mg/day (40 mg for 
the first month) or matched placebo. The patients were in trial for 
2 years. The primary outcome was change in whole brain volume as 
measured by the Brain Boundary Shift Integral (BBSI), with MRI 
data acquired at baseline, 12 months and 25 months; the last MRI 
scan (25 months) was carried out 1 month after last medication 
to minimize any potential artefactual changes in volume1. Simv-
astatin treatment resulted in a highly statistically significant 43% 
reduction in the annualized rate of brain atrophy1, and significant 
changes were also seen in certain clinician- and patient-reported 
outcome measures. As control groups in the haemoglobin assays, 
we studied healthy adult volunteers (n=20); patients with human 
T-lymphotropic virus (HTLV-1)-associated myelopathy/tropical 
spastic paraparesis (HAM/TSP), which closely resembles chronic 
spinal forms of multiple sclerosis (n=20); and asymptomatic 
HTLV-1 carriers (n=20).
Protein profiling of serum by SELDI-TOF mass spectrometry
SELDI-TOF mass spectrometry was performed on 475 serum 
samples collected at baseline, 6 month, 12 months and 24 
months. Samples were randomized, and staff were blinded to the 
treatment arms. CM10 ProteinChip arrays (Bio-Rad Laboratories) 
were primed with binding buffer (50 mM ammonium acetate, 
 0.01% Triton X-100, pH 4·0) and incubated at room temperature 
(RT) for 5 min. A 1:10 dilution of serum in binding buffer was 
then applied to the array and incubated at RT for 1 hr. The arrays 
were washed twice with binding buffer and deionized water. 
Saturated sinapinic acid (0.7 µL) was applied twice to each spot 
on the arrays. Time-of-flight spectra were generated using a 
PCS-4000 mass spectrometer (Bio-Rad). Low-range spectra (mass/
charge (m/z) ratio 0 – 20,000) were obtained at a laser energy of 
3000 nJ, with a focus mass of 6000 and the matrix attenuated to 
1000. High-range spectra (m/z 10,000 – 75,000) were obtained at 
a laser energy of 3900 nJ, with a focus mass of 30,000 and the 
matrix attenuated to 10,000. Mass accuracy was calibrated exter-
nally using All-in-One Peptide or Protein molecular mass standards 
(Bio-Rad).
Proteomics data processing
Spectra were analysed using ProteinChip Data Manager (Bio-Rad 
version 4.1.0) and normalized using total ion current. Peaks were 
auto-detected using a peak threshold of 12.5% and a mass window 
of 0.3%, and the resulting data were converted for subsequent 
analysis using R software. The abundance (intensity) of a given 
protein peak was quantified as the area under the peak; peak 
intensities were log-transformed before analysis. After exclusion of 
one contaminated sample and 4 technical failures, the proteomics 
data consisted of 470 spectra from 138 patients.
Protein enrichment and identification
Ten µL serum were applied to Top 12 Abundant Protein Depletion 
Spin Columns (Thermo Scientific Pierce) according to the manu-
facturer’s protocol. Five hundred µL of the eluate were concentrated 
on a 3 kDa molecular weight cut-off column (Amicon) in 25 mM 
Tris-HCl, pH 8.0. Twenty µL of depleted serum were separated 
by 1D SDS-PAGE on an 18% Tris-glycine denaturing gel (TGX, 
Bio-Rad) at 150 V for 70 min and compared against SeeBlue 
Plus 2 pre-stained protein standard (Life Technologies). The gel 
was rinsed 5 times with deionized water and stained overnight in 
See Band staining solution (Gene Bio-Application Ltd.) A band 
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corresponding to 15 to 16 kDa was excised and an in-gel trypsin 
digest13 was carried out.
Samples were analysed by nanoscale liquid chromatography- 
electrospray ionization tandem mass spectrometry (LC-MS/MS), 
using a nanoAcquity UPLC system (Waters MS Technologies, 
Manchester, UK). Peptide identification was performed using 
ProteinLynx Global SERVER v3.1 (Waters). 
Serum haemoglobin concentration
Free haemoglobin levels were assayed by ELISA (Abcam 
ab157707) according to the manufacturer’s protocol. Samples 
were analysed in random order, and staff were blinded to the treat-
ment arms. Absorbance was measured at 450 nm on a SpectraMax 
microplate reader (Molecular Devices).
Serum lactate dehydrogenase (LDH) activity
Serum LDH activity was assayed by the conversion of lactate to 
pyruvate, using the absorption of light at 340 nm by the reaction 
product NADH (Abbott Laboratories, ref. 7D69).
Statistics
All statistical models were carried out using R 3.2.1 software14. To 
test for associations between SELDI-TOF mass spectrometry peak 
intensity changes and treatment group, linear regression models 
were fitted separately for each spectral peak at each follow-up time 
(6, 12 and 24 months), modelling log(peak intensity change from 
baseline) as a function of baseline log(peak intensity), treatment 
group, and the five randomization variables (age, gender, EDSS 
[Expanded Disability Severity Scale], neuroscience centre, and 
assessing physician).
To test for associations between peak intensity changes and brain 
volume changes, for each pair of time points (0–12 months, 
0–25 months and 12–25 months) the BBSI was compared with 
the change in each peak intensity. Linear regression was used to 
model the log(change in peak intensity) as a function of BBSI 
(expressed as a percentage of baseline whole-brain volume), 
adjusted for baseline log(peak intensity), MRI centre, and the five 
randomization variables.
For both treatment and brain volume analyses, sensitivity analysis 
was carried out using repeated-measures models including all 
four time points. Protein peaks whose regression coefficients 
differed significantly from zero (Wald test) were selected for 
further analysis. To take into account multiple testing, the p-value 
foreach peak was converted into the False Discovery Rate (FDR: 
expected proportion of false positives) for that p-value threshold, 
using the R package fdrtool15. Peaks at FDR ≤ 0.2 were retained for 
further analysis.
The results of the haemoglobin ELISA and the serum LDH assay 
were analysed using two-tailed Mann-Whitney tests to test for 
pairwise differences between the subject groups.
Results
Intensity of specific protein peaks was associated with 
change in brain volume
Expression-difference mapping of all longitudinal serum samples 
(peak threshold of 12.5%; mass window of 0.3% minimum) 
resulted in detection of 145 peaks that were differentially expressed 
within individual subjects over time.
To determine whether changes in protein levels (SELDI-TOF 
peak intensity) were associated with simvastatin treatment, we ran 
regression models for the change in each protein peak intensity vs. 
treatment status, adjusting for the 5 randomization variables and 
MRI centre. No association remained significant after adjusting for 
multiple comparisons (the lowest level at which the FDR could be 
controlled was 0.3).
We next ran regression models for change in protein intensity 
v. brain volume loss, for each interval in which the BBSI was 
measured (0 to 12 months; 12 to 25 months) and over the whole 
trial period (0 to 25 months). The changes in intensity of peaks 
at m/z = 25,110 and 25,402 were significantly associated with the 
change in brain volume between baseline and 12 months (p=0.001, 
corresponding to FDR = 0.08). The regression coefficients for the 
association were negative, i.e. an increase in these protein intensi-
ties was associated with a smaller decrease in brain volume. The 
change in intensity of the peaks at m/z = 15,141 and 15,885 between 
baseline and 25 months was significant in each case (p=0.003 and 
0.001 respectively), corresponding to a FDR of 0.2. For these 
peaks the regression coefficients were positive, i.e. an increase in 
these peaks was associated with a larger decrease in brain volume 
(Figure 1). There were no significant regression coefficients 
for the 12 to 25 month time period. Repeated-measures models 
for the whole time period of the trial also identified the peaks at 
m/z = 15,141 and 15,885 as significant at an FDR of 0.2.
Multiple regression analysis, modelling brain volume change as 
a function of protein peak intensity, treatment status, and the five 
randomization variables and MRI centre as covariates confirmed 
(Table 1) that simvastatin treatment and the protein peak intensity 
were independently associated with the rate of brain atrophy.
The multiple regression model (Table 1) explained 25% of the 
observed variation in the rate of brain atrophy over the two-year 
observation period; the protein peak at 15.1 kDa alone explained 
10% of this variation. The regression coefficient of -0.6 for 
simvastatin treatment indicates a mean difference in brain atrophy 
rate between treatment groups of -0.6% over the 2-year trial period; 
this estimate (-0.3%/year) is consistent with the rate of -0.25%/year 
previously reported in the MS-STAT trial1. The regression coeffi-
cient of 0.75 for BBSI v. protein change means that two patients 
whose protein increases differ by 30% have an expected difference 
in brain atrophy rate of 0.1% over two years (the patient with higher 
increase in protein 15.1kDa expects a greater decrease in brain 
volume).
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Figure 1. Change in intensity of 15.1 kDa peak correlated with rate of brain atrophy. Normalized log(change in intensity of 15.1 kDa peak 
between baseline and 2-year follow-up) versus percentage decrease in brain volume between baseline and 2 years. Solid line shows the 
best fit from the linear regression model (regression coefficient = 0.12, p=0·001). Protein ratios were normalized to all other covariates, using 
the linear regression model. Crosses represent treated individuals, circles represent untreated individuals. The correlation with the 15.9 kDa 
peak was closely similar (regression coefficient = 0.12, p=0·001).
Table 1. Multiple linear regression analysis of the association 
between change in brain volume and change in the peak intensity of 
the proteins whose changes were found to be significantly correlated 
with change in brain volume. Beta = regression coefficient. The model is 
adjusted for the 5 randomization variables and MRI centre.
m/z 15885 (0 to 25 months) m/z 15141 (0 to 25 months)
Beta (95% CI) p Beta (95% CI) p
protein 0.83 (0.33, 1.33) 0.001 0.75 (0.29, 1.22) 0.002
treatment -0·62 (-1.06, -0.19) 0.005 -0.60 (-1.03, -0.17) 0.007
m/z 25110 (0 to 12 months) m/z 25402 (0 to 12 months)
Beta (95% CI) p Beta (95% CI) p
protein -0.99 (-1.72, -0.26) 0.008 -0.73 (-1.37, -0.09) 0.025
treatment -0.26 (-0.56, -0.04) 0.090 -0.27 (-0.58, -0.04) 0.083
Identification of proteins associated with brain atrophy
After enrichment, the intensity of the protein peaks at 25.1 kDa 
and 25.4 kDa remained insufficient to allow their isolation and 
identification. However, the peaks at 15.1 kDa and 15.9 kDa 
remained at high intensities and distinct from nearby peaks 
(Figure 2). LC-MS/MS identified twenty-six peptide fragments 
matching human proteins: 15 fragments corresponded to human 
α-haemoglobin and the remaining 11 fragments corresponded to 
β-haemoglobin (Table 2; Supplementary Table 1). Of the remaining 
364 sequence matches (after exclusion of bacterial sequences and 
the common contaminant keratin), the top 360 were partial matches 
to haemoglobin subunits of other mammalian species.
ELISA confirms the presence of free serum haemoglobin in 
MS patients
We assayed free haemoglobin by ELISA in MS patients (n=20) 
and in three control groups (n=20 in each group; Materials and 
Methods). The results (Figure 3A) showed significantly higher 
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Figure 2. SELDI-TOF mass spectrometry spectra of 15.1 kDa and 15.9 kDa peaks. (A.) Following enrichment on Top 12 Protein Depletion 
column and (B.) Concentration of eluate on 3 kDa molecular weight cutoff column.
Table 2. Identification of peptide fragments from 15.1 kDa and 15.9 kDa protein peaks, 
using LC-MS/MS. *oxidation of M(1). **oxidation of M(15).
Peak m/z Protein name Accession no. 
(UniProt)
PLGS 
score
Peptide matches
1 15,141 Haemoglobin  
alpha
P69905 2049 (R)VDPVNFK(L)  
(R)MFLSFPTTK(T)*  
(K)VGGHAAEYGAEALER(M) 
(R)MFLSFPTTK(T)
2 15,885 Haemoglobin  
beta
P68871 2579 (R)FFESFGDLSTPDAVMGNPK(V)** 
(R)LLVVYPWTQR(F)  
(K)EFTPPVQAAYQK(V)  
(R)FFESFGDLSTPDAVMGNPK(V)  
(K)LHVDPENFR(L)
concentrations of free haemoglobin in the serum from MS 
patients, when compared to each control group (p<0.001 in each 
comparison; Mann-Whitney). Of the 20 MS patients assayed, 17 
had a serum haemoglobin concentration greater than the mean 
+ 2 standard errors of the healthy adult controls. No significant 
difference was observed between the three control groups.
Abnormally high serum LDH activity in MS patients
The presence of free haemoglobin in the serum in MS patients 
suggested a degree of intravascular haemolysis in these individu-
als. To seek corroborative evidence of haemolysis, we assayed 
the serum LDH activity. The median LDH activity in the patients 
with MS was significantly greater than that in each of the three 
control groups (Figure 3B; p<10-12 in each case; Mann-Whitney); 
no significant difference was found between the three con-
trol groups, in each of which the LDH was within the normal 
range.
The mean erythrocyte count, haematocrit and total blood hae-
moglobin in the cohort were within the normal range (see Data 
availability), and there was no association between these 
parameters and the rate of brain atrophy.
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AB
Figure 3. Free serum haemoglobin and lactate dehydrogenase are raised in secondary progressive multiple sclerosis. A. Serum 
haemoglobin concentration measured by ELISA in asymptomatic carriers of HTLV-1 (AC), patients with HTLV-1-associated myelopathy (HAM), 
uninfected, healthy controls (HC), and patients with secondary progressive MS. Log [haemoglobin] by ELISA was significantly correlated with 
log(peak intensity): r = 0.52; p = 0.02; linear regression. B. Serum lactate dehydrogenase (LDH) activity in the same groups of subjects.
Discussion
The characteristic pathological feature of early, active multiple 
sclerosis lesions is primary demyelination, with partial preserva-
tion of axons. But the dominant feature in progressive disease is 
neurodegeneration, which results in brain atrophy. Factors asso-
ciated with this neurodegeneration5 include microglial activation, 
chronic oxidative injury, mitochondrial damage in axons, and iron 
accumulation. A strong correlate of neurodegeneration in MS is 
abnormal iron deposition in both grey and white matter in MS, 
especially along veins and venules in cerebral MS plaques16,17. 
Iron can potentiate oxidative damage by generating hydroxyl radi-
cals by the Fenton reaction. The extent of iron accumulation, as 
indicated by T2 signal hypointensity on MRI, is correlated 
with disease progression, lesion accumulation and cell death of 
oligodendrocytes18–20. The extent of iron deposition is greater in 
SPMS than in relapsing-remitting disease18.
The source of this abnormal iron deposited in the central nerv-
ous system in MS is unknown. Iron is liberated from damaged 
oligodendrocytes and myelin21 and accumulates in macrophages 
and microglia at the margin of active lesions, but it remains unclear 
whether this is the principal source of the iron that accumulates 
in the vessel walls and perivascular space. Bamm and Harauz22 
proposed that chronic extravasation of red blood cells is a source 
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of the abnormal iron deposits; however, neuropathological evi-
dence does not show frequent or widespread extravascular erythro-
cytes in the MS brain.
The results presented here show that a rise in the concentration 
of free haemoglobin in the serum was associated with the rate of 
brain atrophy in this cohort of patients with SPMS. This effect was 
independent of the beneficial treatment effect of simvastatin, 
because there was no association between free haemoglobin con-
centration and simvastatin treatment. Since a successful response 
to simvastatin treatment was not associated with the free serum 
haemoglobin concentration, we infer that the change in free serum 
haemoglobin was not a consequence of brain atrophy but preceded 
brain atrophy in the causal pathway.
These results suggest the hypothesis that chronic, low-grade 
intravascular haemolysis releases haemoglobin into the serum, 
which is then translocated into the CNS parenchyma across the 
impaired blood-brain barrier and potentiates oxidative damage to 
oligodendrocytes. Cytotoxicity by free haemoglobin can be medi-
ated by intact haemoglobin itself, by haem, or by iron, especially 
as Fe2+ 22. Free haemoglobin is degraded by haem oxygenase-1 
(HO-1), producing biliverdin and Fe2+ ions. HO-1 is upregulated 
in glia by oxidative stress, and HO-1 is expressed in oligodendro-
cytes in actively demyelinating areas in MS, but not in two other 
CNS diseases, human acute disseminated leukoencephalomyeli-
tis (ADEM) or murine experimental allergic encephalomyelitis 
(EAE)23. Stahnke et al.23 proposed that the role of stress-induced 
HO-1 is protective initially, whereas chronic upregulation might 
cause oligodendrocyte death.
The observation (Figure 3B) of abnormally high serum LDH 
activity is consistent with the presence of haemolysis in these 
patients. LDH is present in all cell types, and serum LDH is raised 
in many inflammatory conditions; however, erythrocytes are par-
ticularly rich in LDH, and serum LDH is a sensitive marker of 
haemolysis. The notion that chronic intravascular haemolysis might 
serve as a source of the iron deposited in MS is also consistent 
with earlier reports of abnormal fragility of erythrocytes. Erythro-
cytes from patients with MS, especially those with active disease, 
are abnormally susceptible to lysis by both mechanical stress24 and 
osmotic stress25. The causes of this erythrocyte fragility remain to 
be identified. Possible artefactual causes of haemolysis, such as 
venepuncture, cannot explain the significant association observed 
here between brain atrophy and free serum haemoglobin.
If intravascular haemolysis indeed occurs in SPMS, the rate of 
red cell destruction is insufficient to reduce the total blood hae-
moglobin, which remained within normal limits in this cohort. 
Neurodegeneration is not a feature of other chronic haemolytic 
conditions, such as spherocytosis or elliptocytosis; however, in 
these conditions the blood-brain barrier is intact, and most erythro-
cyte destruction occurs in the spleen, where efficient phagocytosis 
may prevent the release of the toxic breakdown products into the 
circulation.
Polymorphisms in genes encoding iron-binding and iron-trans-
porting proteins are associated with disability, disease severity 
and early progression in MS26. Rithidech et al.27 used 2D elec-
trophoresis to identify plasma biomarkers in paediatric MS: the 
haem-bindingprotein haemopexin was 1 of 12 proteins found to be 
upregulated in 9 MS patients. Robotti et al.28 identified an alteration 
in the ratio of isoforms of haptoglobin (which bind free haemo-
globin) in MS.
These results do not suggest that free serum haemoglobin 
concentration is useful in the differential diagnosis of neurological 
disease; rather, they identify a potential contributor to the patho-
genesis of neurodegeneration in progressive multiple sclerosis.
Previous studies of serum iron have shown normal concentrations 
in the serum in patients with MS29; however, standard assays of 
free serum iron do not detect iron that is sequestered in haemo-
globin. Iron chelation has been proposed as a therapy to approach to 
reduce neurodegeneration in MS. However, if an important source 
of iron is free serum haemoglobin, standard iron-chelating agents 
such as desferrioxamine will be ineffective, again because the iron 
is sequestered in haemoglobin30. Scavengers of haemoglobin and 
haemin31 might be more effective.
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,  Franz Fazekas Michael Khalil
Department of Neurology, Medical University of Graz, Graz, Austria
This is an interesting study linking an increase of serum hemoglobin to brain atrophy in patients with
secondary progressive multiple sclerosis. In this study 140 patients have been included, who were initially
recruited for the phase 2, placebo-controlled MS-STAT trial, investigating the effect of simvastatin on
brain volume loss after 2 years of treatment. A total of 475 serum samples collected at baseline, 6
months, 12 and 24 months have been analyzed using an unbiased search for protein profiles by
SELDI-TOF mass spectrometry. Brain volume changes were measured by MRI Brain Boundary Shift
Integral (BBSI) at baseline, 12 months and 25 months.
An increased abundance of serum proteins at 15.1 kDa and 15.9 kDa were significantly correlated to the
rate of brain atrophy after 2 years. These proteins have then been identified as alpha-hemoglobin and
beta hemoglobin using tandem mass spectrometry. In addition, higher serum hemoglobin concentration in
SPMS patients compared to controls has been confirmed using ELISA. The authors further studied serum
lactate dehydrogenase activity, which has also been shown to be significantly increased in SPMS
compared to controls.
It was concluded that a low-grade chronic intravascular hemolysis, which is a potential source of iron
whose deposition along blood vessels in multiple sclerosis plaques contributes to neurodegeneration and
brain atrophy in progressive MS.
 
The results of this study are intriguing and underline other reports on the possible implication of
hemoglobin in the pathogenesis of multiple sclerosis, reviewed in Altinoz  (2016). Lewin et al. et al.
hypothesize that increased serum levels of free hemoglobin may trigger iron deposition along blood
vessels in MS, which could then propagate neurodegeneration and brain atrophy. While this speculation
brings in a new idea, it appears biologically difficult how these processes (e.g. iron deposition along blood
vessels in MS lesions and cortical atrophy) should be so tightly linked in time if at all. Otherwise increased
iron deposition has been shown to occur in MS using several MRI techniques although due to technical
reasons robust quantification of brain iron deposition is currently limited to deep gray matter areas
(Ropele  2011). Longitudinal studies are still scarce, but a recent report indicates that increased brainet al.
iron deposition is more pronounced in early phases of the disease (Khalil  2015). Less informationet al.
exists on progressive forms of MS but one would speculate that the damaging effects from iron deposition
are a long-standing rather than an immediate effect as suggested by Lewin . Observed correlation et al.
thus are likely not able to clarify if and to which extent increased brain iron deposition really amplifies
neurodegeneration in MS or merely reflects an epiphenomenon of the disease. There is also some
evidence for alterations of iron related proteins in CSF and serum of MS patients, including transferrin
(Khalil  2014)  and lipocalin 2 (Khalil  2016), and which may contribute to iron accumulation.et al.  et al.
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evidence for alterations of iron related proteins in CSF and serum of MS patients, including transferrin
(Khalil  2014)  and lipocalin 2 (Khalil  2016), and which may contribute to iron accumulation.et al.  et al.
 
Reiterating some of the concerns and comments of the other reviewers we thus see the need to put
reported findings in a more cautious context. Also some methodological issues deserve clarification.
 
Major comments
The authors should rather use the term “correlated” instead of “associated” and discuss that
presented observations do not prove causality as outlined above.
 
For the same reasons the authors should also avoid to embark on therapeutic speculations.
 
The authors state that they analyzed 475 serum samples at different time points (0, 6, 12 and 24
months), however they do not indicate later on how they used the time point a 6 months. Please
clarify.
 
It is not clear why the confirmative analysis of free serum hemoglobin using ELISA has only been
performed in 20 SPMS patients. It would have been advantageous and the authors a strongly
encouraged to determine free serum hemoglobin in all 475 serum to see if increased free serum
hemoglobin as determined by ELISA was also correlated with increased brain atrophy.
 
The Discussion should also reflect still existing uncertainties in a more comprehensive manner.
 
Minor comments
In Figure 3, p-values (corrected for multiple comparisons) of group differences should be included.
 
In Figure legend 3 it is mentioned that “...Log [haemoglobin] by ELISA was significantly correlated
with log(peak intensity): r = 0.52; p = 0.02; linear regression...”. For better understanding and
reading this information should be presented by a separate scatter plot.
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We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard, however we have significant reservations,
as outlined above.
 No competing interests were disclosed.Competing Interests:
 21 November 2016Referee Report
doi:10.21956/wellcomeopenres.10742.r17825
,  George Harauz Vladimir V. Bamm
Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON, Canada
Summary – This article describes a proteomics analysis of serum proteins derived from 140 patients with
secondary progressive multiple sclerosis (MS), 20 healthy adult volunteers, 20 patients with human
Tlymphotropic virus (HTLV1) causing symptoms resembling spinal MS, and 20  asymptomatic HTLV1
carriers. Half of the MS patients were undergoing treatment with simvastatin,  a drug used to lower blood
cholesterol and shown to have immunomodulatory and anti-inflammatory properties. Protein profiling of
sera was achieved by mass spectrometry of 475 serum samples collected at 0, 12, and 24 months. (A
6month time point is mentioned in some places and is queried below). The MS patients had concurrent
MRI scans at 0, 12, and 25 months to measure whole brain volume (BBSI – brain boundary shift integral),
presumably amongst other measures. Serum samples were “enriched” and analysed by 1D SDSPAGE
followed by LCMS/MS of in gel digested protein. Free haemoglobin (Hb) levels were assessed by ELISA,
and activity of lactate dehydrogenase (LDH), an indicator of general tissue damage, and particularly of
haemolysis was measured. The proteomics analysis suggested that a 15.1kDa protein peak correlated
with the rate of brain atrophy in seemingly all MS patients, regardless of treatment regime. Following
protein enrichment, 15.1kDa and 15.9kDa peaks were observed and confirmed to represent the α and
β-chains of haemoglobin, respectively. In all MS patients, levels of both free Hb chains and of LDH activity
were elevated compared to all controls. The results are consistent with the idea that Hb is released into
serum by chronic and lowgrade intravascular haemolysis, with subsequent  translocation into the CNS
where it has great potential to cause oxidative damage.    
 –Comments on title and abstract
We suggest that the word “associated” needs to be substituted by “correlated”
 
Conclusions in the abstract must be linked to the objectives of the study rather than be a
 speculative claim.    
 – Several points require clarification, in our view.  Comments on study design and data interpretation
 
There were 140 patents, and 60 controls (3 groups of 20). So the total number is supposed to be
 200 serum samples per time point. What are the other 275 samples? The question of sample
numbers, both of patients and controls, arises again later when 138 patients are mentioned.
Additionally, a valuable control could be a group of patients with another neurodegenerative
disease characterised by brain atrophy.    
 
The 6month time point was not mentioned in the paragraph describing the study design, and there
were no results reported for it.
 
For protein profiling by SELDITOF mass spectrometry, after the 1:10 serum dilution, one would
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For protein profiling by SELDITOF mass spectrometry, after the 1:10 serum dilution, one would
 expect signal suppression effect on the lower abundance proteins. To remove this effect it would
have been advised to fractionate the serum first, and then use protein chip arrays. Since the
authors did not fractionate the sera, it is not possible to rule out other lowerabundance markers,
such as hemopexin, as we indicate next.
 
The Top 12 Protein Depletion Spin Columns are a good way to partially fractionate the serum or to
enrich the protein of interest. However, several very important proteins (haptoglobin, transferrin,
and Apo AI) related to iron homeostasis will be removed by this procedure. In the context of this
study, it is important to see the specific expression patterns of haptoglobin, hemopexin, and HO1
since they represent different levels of defence mechanisms against extracellular Hb. Also, it could
be beneficial to try and correlate different haptoglobin phenotypes with BBSI.
 
In the same vein, the ELISA kit will detect extracellular Hb from two sources: free Hb and
haptoglobinbound Hb. The latter form could have been removed by the spin column that was used
for protein enrichment.
 
Why and how were only 20 patients selected for ELISA?    
 – We believe that the Discussion can be augmented to give a broader pictureComments on discussion
as follows. 
Association versus correlation of brain volume and Hb levels. In our opinion the results
show correlation between brain volume and free Hb levels and are insufficient to claim that these
two factors are “associated” per se.
 
In reference to [(Bamm and Harauz 2014)], the authors state that “neuropathological evidence
does not show frequent or widespread extravascular erythrocytes in the MS brain”. This statement
is not strictly correct. Firstly, in [(Bamm and Harauz 2014)] we did not suggest that
chronic extravasation of red blood cells is an exclusive source of the abnormal iron deposits. In
fact, we said:  “Any type of seemingly minor yet chronic cerebrovascular abnormality and/or
damage to the blood– brain barrier, … , can potentially lead to , or to intravascular hemolysis
extravasation of erythrocytes and extravascular hemolysis”. Secondly, as we reviewed recently
[(Bamm et al. 2016)], extracellular Hb could arise from blood extravasation due to capillary and
venous microhemorrhages, which ARE being documented in MS lesions, as possibly are cerebral
microbleeds (CBMs) [(Zivadinov  2016)]. Such events can be difficult to detect at theet al.
histological level, especially in the early stages of lesion formation that can arise from molecular
dysfunction rather than gross structural damage. The  potential molecular mechanisms of Hb
toxicity in myelin are described in a subsequent experimental  paper [(Bamm  2015)] and doet al.
not rely on largescale iron deposition. The damage inflicted by free Hb can arise at many different
levels and per se will not necessarily be associated with the number of extravasated erythrocytes
in MS tissue.
 
In reference to erythrocyte fragility in MS, we suggest also citing one of the earlier papers to
indicate that this is an old idea that has been insufficiently explored [(Caspary 1967)], and twoet al.
newer papers that describe the association of haemoglobin variants with MS severity [(Altinoz et al.
2016; Ozcan  2016)].et al.
 
It is not clear how the finding of higher free Hb in the sera of MS patients can be explained. The
 authors reported that the mean erythrocytes count and total blood Hb did not differ between MS
patients and control groups. However, the MS patients were characterized by the
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patients and control groups. However, the MS patients were characterized by the
increased presence of free Hb. If a simple formula for total Hb is: Hb within the erythrocytes +
cellfree Hb, and the erythrocyte count was similar, then the amounts of cellfree Hb should be
similar. Is the morphology of erythrocytes from MS patients and controls different? Perhaps the
erythrocytes from MS patients were hypochromic (less intracellular Hb)? We believe that the
authors should clarify this  point.  
 
The first line of defense against extracellular haemoglobin is haptoglobin (Hpt). We
have determined recently that the frequency of the hpt1 allele is lower in Australia, and in European
and North American countries with a high reported prevalence of MS [(Bamm  2016)]. Weet al.
also recommended an epidemiological study to evaluate the potential association of Hpt
phenotype with disease severity and/or comorbidity with cardiovascular disorders, as is being
done for Parkinsonism  [(CostaMallen  2015; Delanghe  2016; CostaMallen  2016)].et al. et al. et al.
It should also be pointed out that cardiovascular disorders have been found to be associated with
disease severity and brain  atrophy in MS [(Kappus  2016)]. This latter reference is certainlyet al.
relevant to the Discussion of this current study.
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We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard, however we have significant reservations,
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 No competing interests were disclosed.Competing Interests:
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,  Hans Lassmann Simon Hametner
Center for Brain Research, Medical University of Vienna, Vienna, Austria
This is a very interesting study providing convincing evidence for an association between the serum level
increases of free haemoglobin with the extent of brain atrophy progression, determined by MRI, in
secondary progressive multiple sclerosis. This was originally observed by the authors using an unbiased
proteomics approach, aimed at determining potential serum biomarkers for disease progression. The
patient collective derives from a well-controlled clinical trial investigating the effect of simvastatin on the
rate of brain atrophy progression in secondary progressive MS. Having found this association, the authors
then confirmed free hemoglobin increase in SPMS patients by an independent approach using ELISA.
The study is very well performed, based on a sound and innovative technology and the results have major
implications for the understanding of the neurodegenerative process in MS. Interestingly, the association
between haemoglobin serum level increase and atrophy rate occurred independently from the effect of
simvastatin treatment. Thus increased haemoglobin in the serum may contribute to the
neurodegenerative process, but there are other mechanisms additionally involved. By showing also
increased levels of serum LDH the authors further support the concept that there is a low degree of
hemolysis in the peripheral blood of MS patients, which however is not reflected in reduction of
erythrocyte counts, haematocrit or total blood haemoglobin. However, it would also be interesting to
address whether there is an association between actual free hemoglobin levels at any of the single time
points (not their change over time), as determined by mass spectrometry, and the observed brain atrophy
rates. Authors only show a positive association of free hemoglobin increase with brain atrophy levels,
which might have a different interpretation than what the authors conclude. Furthermore, the quantitative
ELISA data are not linked with MRI brain atrophy rates. Were the 20 MS patients included in the ELISA
quantification taken from the big cohort of the proteomics part of the study? Then MRI data would be
available, and the analysis could be easily performed.
There is good indirect evidence that iron loading of the brain may be involved in neurodegeneration in MS
through the amplification of oxidative injury. So far, the mechanisms how the human brain is loaded with
iron during aging and in the disease process of MS is not fully understood. This study indicates that heme
iron, derived from free circulating haemoglobin, may be of major importance in brain iron accumulation in
the course of multiple sclerosis. Free hemoglobin, presumably bound to the haemoglobin scavenger
haptoglobin, might diffuse into the brain via a partially compromised blood-brain barrier and might lead to
iron accumulation within MS basal ganglia and microglia at edges of chronic lesions. The key question,
which however remains unresolved here, concerns the cause of increased free haemoglobin in the blood
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which however remains unresolved here, concerns the cause of increased free haemoglobin in the blood
of MS patients. Interestingly, it has already been shown in the late 1960ths that erythrocyte diameters are
larger in MS patients (J. Prineas,1968) and that there is a higher fragility of erythrocytes in comparison to
controls, which may result in liberation of haemoglobin (E.A. Caspary ,1967). These observationset al.
together with more recent findings, which relate them to other disturbances of iron homeostasis in MS,
have been recently discussed in a comprehensive review article (Altinoz  2016). Whether theet al.,
increased erythrocyte fragility is a genuine metabolic problem or a consequence of a general systemic
chronic pro-inflammatory environment in the MS patients is currently unresolved.
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Version 1
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, Department of Immunology, Imperial College London, UKCharles Bangham
Lewin  – response to reviewerset al.
We thank the three pairs of reviewers of our article, each of whom made helpful suggestions and raised
salient points for clarification or further discussion. We have revised the article in the light of these
comments, and cite further relevant literature (8 references have been added). The response to individual
points is given below.
 
Review 1
Referee Report 18 Nov 2016 
Hans Lassmann, Center for Brain Research, Medical University of Vienna, Vienna, Austria 
Simon Hametner, Center for Brain Research, Medical University of Vienna, Vienna, Austria 
 
Approved 
 
DOI: 10.21956/wellcomeopenres.10742.r17609
 
 
We thank the reviewers for their comments. We have included the three papers suggested in the revised
version of the paper.
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We thank the reviewers for their comments. We have included the three papers suggested in the revised
version of the paper.
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READ ALL
Comments on title and abstract –
       1. We suggest that the word “associated” needs to be substituted by “correlated”
In standard usage, “associated” has a broader, less specific meaning than “correlation”, and it does not
imply causation. We would like to keep the term.
       2. Conclusions in the abstract must be linked to the objectives of the study rather than be a
 speculative claim.    
We like the phrasing used by the reviewers at the end of their summary, and we have adapted it in the
Conclusions section of the revised version of the abstract, to clarify the hypothesis and to avoid
speculation.
Comments on study design and data interpretation – Several points require clarification, in our
view.    
       
       1. There were 140 patents, and 60 controls (3 groups of 20). So the total number is supposed
to be  200 serum samples per time point. What are the other 275 samples? The question of
sample numbers, both of patients and controls, arises again later when 138 patients are
mentioned. Additionally, a valuable control could be a group of patients with another
neurodegenerative disease characterised by brain atrophy.
The proteomic screen was carried out on the 140 SPMS patients in the MS-STAT trial, which did not
include subjects without MS. There were 4 time-points, giving a potential total of 560 serum samples;
however, samples were not available from all patients at each time-point. We have clarified these points in
the revised text. 
It will indeed be interesting to study the serum proteome in other neurodegenerative diseases, as the
reviewers indicate.
       2. The 6month time point was not mentioned in the paragraph describing the study design,
and there were no results reported for it.  
Thank you for pointing this out. We have amended the relevant section - paragraph 2 in the Results – to
explain that data from each of the three follow-up visits (including the 6-month time point) were compared
against the baseline.
       3. For protein profiling by SELDITOF mass spectrometry, after the 1:10 serum dilution, one
would  expect signal suppression effect on the lower abundance proteins. To remove this effect
it would have been advised to fractionate the serum first, and then use protein chip arrays. Since
the authors did not fractionate the sera, it is not possible to rule out other lowerabundance
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the authors did not fractionate the sera, it is not possible to rule out other lowerabundance
markers, such as hemopexin, as we indicate next. 
The reviewers are of course correct that we cannot exclude the possibility that other, lower-abundance
markers are also correlated with brain atrophy rate, in addition to the correlation with free serum
haemoglobin reported in the present study. Other markers could be sought both by fractionating diluted
serum and by using other surfaces in the SELDI protocol, in order to select subsets of proteins with
different profiles of hydrophobicity, charge etc. We have added a sentence to the text (Discussion section)
to point out these considerations.
       4. The Top 12 Protein Depletion Spin Columns are a good way to partially fractionate the
serum or to enrich the protein of interest. However, several very important proteins (haptoglobin,
transferrin, and Apo AI) related to iron homeostasis will be removed by this procedure. In the
context of this study, it is important to see the specific expression patterns of haptoglobin,
hemopexin, and HO1 since they represent different levels of defence mechanisms against
extracellular Hb. Also, it could be beneficial to try and correlate different haptoglobin phenotypes
with BBSI. 
We apologize for not making this clear. The SELDI procedure, which led to the detection of the two
correlated peaks, was carried out on whole sera, not after depletion of the abundant serum proteins; the
Top 12 Protein Depletion Spin Columns were used subsequently, to enrich the peaks for identification by
LC-MS/MS. We have added a sentence to the beginning of the relevant paragraph in the Materials and
Methods section to clarify this.
       5. In the same vein, the ELISA kit will detect extracellular Hb from two sources: free Hb and
haptoglobinbound Hb. The latter form could have been removed by the spin column that was
used for protein enrichment.
The reviewers are correct that the anti-human haemoglobin polyclonal antibody in the ELISA kit should
detect both free and haptoglobin-bound Hb, although the manufacturers have not tested this. In order to
detect only free Hb, Top 12 depletion columns could be used to remove haptoglobin-bound Hb. However,
in our results the Top 12 depletion columns increased the relative abundance of the two candidate peaks
(15.1 kDa and 15.9 kDa), rather than depleting them, suggesting that the bulk of the Hb was not bound to
haptoglobin.
       6. Why and how were only 20 patients selected for ELISA?
The ELISA was carried out for two purposes. First, to test whether the concentration of free serum
haemoglobin in these samples was in the range measurable by a standard commercial assay, and was not
only detectable by mass spectrometry. Second, to test whether the ELISA measurements correlated with
the intensity of the protein peaks in the SELDI data. For these purposes we assayed a randomly-chosen
subset of 20 sera; the results established both of the points we set out to test.
Comments on discussion – We believe that the Discussion can be augmented to give a broader
picture as follows. 
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       1. Association versus correlation of brain volume and Hb levels. In our opinion the results
show correlation between brain volume and free Hb levels and are insufficient to claim that these
two factors are “associated” per se. 
As noted above, we use the term “associated” in its standard, broad sense; the term does not imply that
this association proves a causal connection, although we postulate this later.
     2. In reference to [(Bamm and Harauz 2014)], the authors state that “neuropathological
evidence does not show frequent or widespread extravascular erythrocytes in the MS brain”.
This statement is not strictly correct. Firstly, in [(Bamm and Harauz 2014)] we did not suggest
that chronic extravasation of red blood cells is an exclusive source of the abnormal iron
deposits. In fact, we said:  “Any type of seemingly minor yet chronic cerebrovascular abnormality
and/or damage to the blood– brain barrier, … , can potentially lead to intravascular hemolysis, or
to extravasation of erythrocytes and extravascular hemolysis”. Secondly, as we reviewed
recently [(Bamm et al. 2016)], extracellular Hb could arise from blood extravasation due to
capillary and venous microhemorrhages, which ARE being documented in MS lesions, as
possibly are cerebral microbleeds (CBMs) [(Zivadinov et al. 2016)]. Such events can be difficult
to detect at the histological level, especially in the early stages of lesion formation that can arise
from molecular dysfunction rather than gross structural damage. The  potential molecular
mechanisms of Hb toxicity in myelin are described in a subsequent experimental  paper [(Bamm
et al. 2015)] and do not rely on largescale iron deposition. The damage inflicted by free Hb can
arise at many different levels and per se will not necessarily be associated with the number of
extravasated erythrocytes in MS tissue.
We accept that current evidence does not exclude extravasation of erythrocytes as a possible cause of
haemoglobin in the CNS parenchyma.  We have amended the text of the Discussion to reflect more
accurately the balanced views expressed in the Bamm and Harauz 2014 paper, and to include citations of
the recent papers noted above.  In the following paragraph, we have also added a citation of the useful
experimental study of haemoglobin toxicity (Bamm et al 2015).
      3. In reference to erythrocyte fragility in MS, we suggest also citing one of the earlier papers
to indicate that this is an old idea that has been insufficiently explored [(Caspary et al.1967)], and
two newer papers that describe the association of haemoglobin variants with MS severity
[(Altinoz et al. 2016; Ozcan et al. 2016)]. 
Thank you for these suggestions. Indeed we did cite Caspary  (1967) in an earlier version of theet al.
manuscript. We have now re-inserted this citation, and the first report of which we are aware of erythrocyte
fragility in MS (Laszlo, 1964); and we have also added references to the very interesting papers recently
published by Altinoz  and Ozcan et al. et al.
       4. It is not clear how the finding of higher free Hb in the sera of MS patients can be explained.
The  authors reported that the mean erythrocytes count and total blood Hb did not differ between
MS patients and control groups. However, the MS patients were characterized by the
increased presence of free Hb. If a simple formula for total Hb is: Hb within the erythrocytes + cell
free Hb, and the erythrocyte count was similar, then the amounts of cellfree Hb should be similar.
Is the morphology of erythrocytes from MS patients and controls different? Perhaps the
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Is the morphology of erythrocytes from MS patients and controls different? Perhaps the
erythrocytes from MS patients were hypochromic (less intracellular Hb)? We believe that the
authors should clarify this  point.  
Thank you for raising this point, which is important to clarify. As shown in Figure 3A, the mean
concentration of free Hb in the serum of the 20 patients assayed was ~300 micrograms/mL, i.e. 30 mg/dL.
Since the haematocrit is ~50%, this concentration is equivalent to ~15 mg/dL of whole blood. This
compares with the total [Hb] in whole blood, which is of the order of 15g/dL. Thus, even the abnormally
high [Hb] accounts for only 0.1% of the total blood haemoglobin, and consequently does not significantly
alter the mean [Hb]. We have added a sentence to the Discussion to note this.
       5. The first line of defense against extracellular haemoglobin is haptoglobin (Hpt). We
have determined recently that the frequency of the hpt1 allele is lower in Australia, and in
European and North American countries with a high reported prevalence of MS [(Bamm et al.
2016)]. We also recommended an epidemiological study to evaluate the potential association of
Hpt phenotype with disease severity and/or comorbidity with cardiovascular disorders, as is
being done for Parkinsonism  [(CostaMallen et al. 2015; Delanghe et al. 2016; CostaMallen et al.
2016)]. It should also be pointed out that cardiovascular disorders have been found to be
associated with disease severity and brain  atrophy in MS [(Kappus et al. 2016)]. This latter
reference is certainly relevant to the Discussion of this current study.
We have added a sentence to the paragraph in the Discussion on genetic polymorphisms to discuss the
possible role of haptoglobin variants, citing Bamm  2016. We have also added a sentence to the firstet al.
paragraph of the Discussion to cite the evidence of Kappus  (2016) that risk factors of cardiovascularet al.
diseases are also associated with lesion burden and brain atrophy in MS.
Review 3
Referee Report 12 Dec 2016
Franz Fazekas, Department of Neurology, Medical University of Graz, Graz, Austria 
Khalil Michael, Department of Neurology, Medical University of Graz, Graz, Austria 
Approved with Reservations
Thank you for the thoughtful comments. The point about the rate at which iron deposition might cause
neurodegeneration is well taken, and in the revised version of the paper we cite the very interesting
longitudinal study of brain iron levels (Khalil  2015: Neurology 84, 2396). However, in our study we et al.
were not able to test hypotheses on the kinetics or the mechanisms of neurodegeneration, which have
been intensively studied by others, including the reviewers. Our results do not imply that the free
haemoglobin detected during the course of the two-year trial caused neural damage during the same
period: it is perhaps more likely that both iron deposition and neurodegeneration were occurring
continously in these patients.
Major comments
The authors should rather use the term “correlated” instead of “associated” and discuss
that presented observations do not prove causality as outlined above.
As noted above, we use the term “associated” in its standard, broad sense; the term does not imply that
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As noted above, we use the term “associated” in its standard, broad sense; the term does not imply that
this association proves a causal connection: although we postulate the direction of causation later, it is
certainly not proved by our present results.
For the same reasons the authors should also avoid to embark on therapeutic
speculations.
We have added a conditional clause to the Abstract (last sentence) to make it clear that chelators of
haemoglobin may be useful therapeutically if indeed free haemoglobin contributes to the pathogenesis of
the neurodegeneration. Similarly, in the final paragraph of the Discussion, we state “However, if an
important source of iron is free serum haemoglobin, standard iron-chelating agents such as
desferrioxamine may be ineffective...”  We think it is important to discuss the possible therapeutic
implications, with due caution, for two reasons: first, because iron chelators are currently being tested
therapeutically in MS, and second, because new therapeutic options are needed.
The authors state that they analyzed 475 serum samples at different time points (0, 6, 12
and 24 months), however they do not indicate later on how they used the time point a 6
months. Please clarify.
Thank you for pointing this out, which was also noted by reviewer 1. Please see response to Reviewer 1,
point 2 above.
It is not clear why the confirmative analysis of free serum hemoglobin using ELISA has
only been performed in 20 SPMS patients. It would have been advantageous and the
authors a strongly encouraged to determine free serum hemoglobin in all 475 serum to see
if increased free serum hemoglobin as determined by ELISA was also correlated with
increased brain atrophy.
Please see response to Reviewer 1, point 6 above.
The Discussion should also reflect still existing uncertainties in a more comprehensive
manner.
We have added further text to make it clear we do not postulate (still less prove) that free haemoglobin is
the sole cause of neurodegeneration in SPMS. We write in the Discussion “These results suggest the
hypothesis...”; “It is possible that other, lower-abundance markers are also correlated with brain atrophy
rate”; “If intravascular haemolysis indeed occurs in SPMS...”; [these results] identify a potential contributor
to the pathogenesis...”; “...if an important source of iron is free serum haemoglobin, standard iron-chelating
agents such as desferrioxamine may be ineffective...”.
 
Minor comments
In Figure 3, p-values (corrected for multiple comparisons) of group differences should be
included.
We have now included the Bonferroni-corrected p values in the figure legend.
In Figure legend 3 it is mentioned that “...Log [haemoglobin] by ELISA was significantly
Page 22 of 23
Wellcome Open Research 2016, 1:10 Last updated: 25 DEC 2016
F1000Research
In Figure legend 3 it is mentioned that “...Log [haemoglobin] by ELISA was significantly
correlated with log(peak intensity): r = 0.52; p = 0.02; linear regression...”. For better
understanding and reading this information should be presented by a separate scatter
plot.
For clearer presentation, we have expanded the sentence reporting this correlation and moved it to the text
in the Results section.
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